NCT07403760Recruiting
Wellbeing and Survival Improvement With Event Reduction by Ablation for Atrial Fibrillation in the Very Elderly
Wellbeing and Survival Improvement With Event Reduction by Ablation for Atrial Fibrillation in the Very Elderly (WISER-AF)
Source: ClinicalTrials.gov · Last updated 6 Jul 2026
Brief summary (registry, in English)
The WISER-AF trial is a multicenter, double-blind, sham-controlled, randomized controlled trial. It aims to evaluate the efficacy and safety of catheter ablation compared to a sham procedure in improving the quality of life (SF-36 score) in very elderly patients (aged ≥80 years) with symptomatic atrial fibrillation over a 6-month follow-up period.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 136 (estimated)
- First submitted
- 4 Feb 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 30 Nov 2028
- Lead sponsor
- Beijing Anzhen Hospital
- Diseases
- Atrial fibrillation
- NCT number
- NCT07403760
What you commit to
- Study type: Interventional
- Planned participants: 136
- From 1 Jul 2026 to the primary completion date, 30 Nov 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of prior AF ablation.
- Prior Left Atrial Appendage Occlusion (LAAO).
Other illness
- NYHA Class IV heart failure.
- Acute myocardial infarction, cardiac surgery, or PCI within the past 1 year.
- AF secondary to reversible causes (e.g., post-surgery, infection, hyperthyroidism).
- Moderate to severe hepatic failure (Child-Pugh B-C).
- Inability to cooperate due to dementia or severe mental disorder.
Lab values
- Renal failure stage 4-5 (eGFR \<30 ml/min/1.73m2) or continuous dialysis.
Other
- Long-standing persistent AF (duration \> 1 year).
- Left atrial anteroposterior diameter \> 6 cm.
- Severe mitral stenosis.
- Presence of left atrial thrombus.
- Contraindication to anticoagulation.
- Life expectancy \< 1 year.
Who the study is looking for
- Age ≥ 80 years.
- Documented paroxysmal or persistent atrial fibrillation by ECG or Holter within 6 months prior to enrollment.
- Symptomatic AF (including palpitations, chest tightness, fatigue, dizziness, blackouts, dyspnea).
- Voluntary participation and signed informed consent.
Age in the registry: 80 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Anzhen Hospital, Capital Medical University, Beijing, China Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.